KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Common Equity (2018 - 2025)

Historic Common Equity for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to $796.1 million.

  • Vir Biotechnology's Common Equity fell 3583.62% to $796.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $796.1 million, marking a year-over-year decrease of 3583.62%. This contributed to the annual value of $1.2 billion for FY2024, which is 2765.95% down from last year.
  • Per Vir Biotechnology's latest filing, its Common Equity stood at $796.1 million for Q3 2025, which was down 3583.62% from $947.5 million recorded in Q2 2025.
  • In the past 5 years, Vir Biotechnology's Common Equity ranged from a high of $2.1 billion in Q3 2022 and a low of $651.0 million during Q1 2021
  • Over the past 5 years, Vir Biotechnology's median Common Equity value was $1.4 billion (recorded in 2024), while the average stood at $1.4 billion.
  • As far as peak fluctuations go, Vir Biotechnology's Common Equity skyrocketed by 20739.86% in 2022, and later crashed by 3583.62% in 2025.
  • Quarter analysis of 5 years shows Vir Biotechnology's Common Equity stood at $1.4 billion in 2021, then soared by 45.12% to $2.1 billion in 2022, then dropped by 23.47% to $1.6 billion in 2023, then fell by 27.66% to $1.2 billion in 2024, then plummeted by 30.8% to $796.1 million in 2025.
  • Its Common Equity stands at $796.1 million for Q3 2025, versus $947.5 million for Q2 2025 and $1.0 billion for Q1 2025.